Article Text

Download PDFPDF
Paediatric autoimmune encephalopathies: a lot done, more to do
  1. Andrew McKeon1,2,
  2. Vanda A Lennon1,2,3
  1. 1Department of Neurology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  2. 2Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  3. 3Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Andrew McKeon Department of Neurology College of Medicine Mayo Clinic 200 1st St SW Rochester MN 55905 USA; mckeon.andrew{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Early recognition of paediatric autoimmune encephalopathies is critical because they are treatable. Serological findings and response to immunotherapy are confirmatory.

The expedited diagnosis of an autoimmune neurological disorder is critical because early treatment facilitates improvement. The data reported by Hacohen et al from a multi-institutional experience of childhood autoimmune encephalopathies should promote early recognition of these disorders.1

Autoimmunity ranks high in the differential diagnosis for encephalopathy. Suspicion is heightened when neuropsychiatric symptom onset is subacute, autoimmunity is recorded in the personal or family history, or serological findings are supportive. Autoantibody detection in serum or cerebrospinal fluid (CSF), with specificities either non-neural (eg, thyroid peroxidase or antinuclear) or neural …

View Full Text


  • Contributors AMK wrote the first draft and critically revised the manuscript. VAL critically revised the manuscript.

  • Funding None.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles